RET and non-small cell lung carcinoma: After the identification of RET fusion in NSCLC by Ju et al. [22], Drilon et al. first reported the clinical activity of cabozantinib (60 mg/day) in three chemo-pretreated NSCLC patients harboring RET fusion [23].